MITOSIS MITOSIS MITOSIS Bio-Marker Composition for Sensitivity Prediction of MITOSIS Drug Estimation Method for Sensitivity Prediction of MITOSIS Drug using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Sensitivity Prediction of MITOSIS Drug

摘要

The present invention relates to a biomarker composition for evaluating MITOSIS drug responsiveness using cancer biomarker labeling scan (GBLscan), which is a new learning model capable of predicting haplotype biomarker containing MITOSIS drug responsiveness functional information, thereby enabling a reliable prediction and drug labeling MITOSIS drug responsiveness. In particular, the present invention relates to a biomarker composition consisting a combination of markers containing mutations regulating gene expressions for evaluation responsiveness with respect to MITOSIS drugs, wherein the biomarker composition comprises 1_85581605_TA_T (Marker 1) and 6_135201764_A_C (Marker 2). According to the present invention, the biomarker composition enables the prediction of sensitivity to MITOSIS drugs by subject′s genotype by means of biomarkers to MITOSIS-related drugs, and thus can enable an effective preliminary testing not only in the field of personalized medicine, but also in screening of new drug candidates.